Citations 1
MyPathway: An open-label phase IIa study of trastuzumab/pertuzumab, erlotinib, vemurafenib, and vismodegib in patients who have advanced solid tumors with mutations or gene expression abnormalities targeted by these agents.
Burris, Howard A. , Hurwitz, Herbert I. , Perez, Edith A. , Hainsworth, John D. , Leon, Larry, Beattie, Mary, Brammer, Melissa, Spigel, David R. , Swanton, Charles , Leon, Larry, Sweeney, Christopher J.
Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: TPS11111-TPS11111
